Skip to search boxSkip to navigationSkip to main content

Tetrahydrobiopterin improves endothelial function in patients with cystic fibrosis

  • Jin Hee Jeong
    ,
  • Nichole Lee
    ,
  • Matthew A. Tucker
    ,
  • Paula Rodriguez-Miguelez
    ,
  • Jacob Looney
    ,
  • Jeffrey Thomas
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

Cystic fibrosis (CF) is a genetic disorder associated with vascular endothelial dysfunction. Nitric oxide (NO) plays a major role in maintaining vascular function, and tetrahydrobiopterin (BH4) is a critical determinant of NO bioavailability. Thus the purpose of this study was to investigate the effects of oral administration of BH4 on endothelial function in patients with CF. Twenty-nine patients with CF (18 8 yr old) and 29 healthy matched controls were recruited. Patients with CF participated in a randomized trial where they received a 5 mg/kg dose of oral BH4 (BH4-5; n 17) or a 20 mg/kg dose of oral BH4 (BH4-20; n 12). On a separate visit, a subset of patients from each group was retested following a placebo (PLC; n 9). Brachial artery flow-mediated dilation (FMD) was used to evaluate vascular endothelial function, and a plasma sample was obtained before and 3 h after treatment. Cultured endothelial cells were treated with plasma to assess NO bioavailability. Baseline FMD was lower in patients compared with controls (5.7 3.4 vs. 8.4 3.5%, respectively, P 0.005). No change in FMD was observed following PLC or BH 4 -5 (FMD: 0.8 1.9% and 0.5 2.5%; P 0.273 and 0.132, respectively). Treatment with BH4-20, however, resulted in significant improvements in FMD (FMD: 1.1 1.4%) compared with BH4-5 (P 0.023) and PLC (P 0.017). Moreover, BH4-20 significantly decreased endothelial cell superoxide production and increased NO production. These data suggest that a single oral dose of BH 4 at 20 mg/kg improves vascular endothelial function in patients with CF, likely via increased endothelial NO synthase coupling. These findings support the hypothesis that loss of BH4 bioactivity contributes, in part, to endothelial dysfunction in patients with CF.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 60-66 (7 pages)

Journal (Volume, Issue Number)

Journal of Applied Physiology (Volume 126, Issue 1)

Publication milestones

  • Published - 01/2019

Publication status

Published - 01/2019

ISSN

8750-7587

Publication IDs

  • Scopus: 85059795819
  • PubMed: 30433862

Publication metrics

Metrics

SciVal
citations
5
Scopus
citations
Fractional count
5
Fractional count
0.36
Fractional count
9
Fractional count
0.64
Fractional count
5
Fractional count
1
SciVal
FWCI
0.79
SciVal
Author count
14
SciVal
Paper percentile
76

PlumX, opens in new tab

Captures
41
Citation count
10
Mentions
1